FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024144538> ?p ?o ?g. }

• W3024144538 endingPage "363" @default.
• W3024144538 startingPage "363" @default.
• W3024144538 abstract "<ns4:p><ns4:bold>Background:</ns4:bold>Patients’ clinical outcomes and pharmacogenetic factors are important predictors of nevirapine (NVP) plasma concentration. This study evaluated the association of socio-demographic factors and Cytochrome P450 2B6 (CYP2B6) polymorphisms with NVP plasma concentrations among patients receiving antiretroviral therapy (ART) treatment in western and coastal Kenya.</ns4:p><ns4:p><ns4:bold>Methods:</ns4:bold>Blood samples were collected from 377 consenting HIV adult patients receiving an NVP-based first-line ART regimen. A detailed sociodemographic questionnaire was administered. NVP plasma concentration was measured by liquid chromatography - tandem mass spectrometry (LC-MS/MS). CYP2B6 c.516 G>T rs3745274 and c.983T>C genotypes were evaluated using real-time polymerase chain reaction. HIV drug resistance mutations were detected using an in-house genotypic assay.</ns4:p><ns4:p><ns4:bold>Results:</ns4:bold>The patients’ mean age was 41.6 (SD ± 11.5) years and the majority (59.2%) were female. The mean duration of ART was 5.1 (SD ± 4.8) years. Overall NVP plasma levels ranged from 4-44207 ng/mL (median 6213 ng/mL, IQR 3097–8606.5 ng/mL). There were 105 (25.5%) participants with NVP levels of <3100 ng/mL, associated with poor viral suppression. Multivariate linear regression analysis showed CYP2B6 516 G>T polymorphism (β 0.71, 95% CI 0.4–0.98; p<0.0001), male gender (β 0.45, 95% CI 0.01–0.9; p<ns4:italic>=</ns4:italic>0.047) and presence of HIV drug-resistant virus (β 1.98, 95% CI 1.24–2.72; p<0.001) were the independent factors influencing NVP plasma concentration.</ns4:p><ns4:p><ns4:bold>Conclusions:</ns4:bold>The majority of patients receiving an NVP-based ART regimen had plasma concentrations within the therapeutic range. CYP2B6 516 G>T polymorphism, gender and presence of a HIV drug-resistant mutation significantly influences NVP plasma concentration. Routine pharmacogenetic testing and measurement of NVP plasma concentrations, considering gender and presence of HIV drug-resistant mutations are key to ensuring optimal ART treatment outcomes in Kenya.</ns4:p>" @default.
• W3024144538 created "2020-05-21" @default.
• W3024144538 creator A5026183878 @default.
• W3024144538 creator A5043189518 @default.
• W3024144538 creator A5067858015 @default.
• W3024144538 creator A5085270072 @default.
• W3024144538 creator A5086190712 @default.
• W3024144538 date "2020-05-14" @default.
• W3024144538 modified "2023-09-27" @default.
• W3024144538 title "Role of pharmacogenetics and clinical parameters on nevirapine plasma concertation among HIV-1 patients receiving Antiretroviral Therapy in Kenya" @default.
• W3024144538 cites W1483859993 @default.
• W3024144538 cites W1940770670 @default.
• W3024144538 cites W1963944716 @default.
• W3024144538 cites W1987178620 @default.
• W3024144538 cites W1994630094 @default.
• W3024144538 cites W1999575113 @default.
• W3024144538 cites W2001964229 @default.
• W3024144538 cites W2035412462 @default.
• W3024144538 cites W2059767880 @default.
• W3024144538 cites W2064210857 @default.
• W3024144538 cites W2064510625 @default.
• W3024144538 cites W2071067871 @default.
• W3024144538 cites W2081935668 @default.
• W3024144538 cites W2094657539 @default.
• W3024144538 cites W2110774735 @default.
• W3024144538 cites W2120761049 @default.
• W3024144538 cites W2123211579 @default.
• W3024144538 cites W2124543441 @default.
• W3024144538 cites W2132535766 @default.
• W3024144538 cites W2135892517 @default.
• W3024144538 cites W2141776019 @default.
• W3024144538 cites W2144545539 @default.
• W3024144538 cites W2154703395 @default.
• W3024144538 cites W2164132972 @default.
• W3024144538 cites W2164216849 @default.
• W3024144538 cites W2166239922 @default.
• W3024144538 cites W2481664921 @default.
• W3024144538 cites W2508295414 @default.
• W3024144538 cites W2589212415 @default.
• W3024144538 cites W2746680674 @default.
• W3024144538 cites W2807061259 @default.
• W3024144538 cites W2949710113 @default.
• W3024144538 cites W3196876339 @default.
• W3024144538 cites W569996699 @default.
• W3024144538 doi "https://doi.org/10.12688/f1000research.22654.1" @default.
• W3024144538 hasPublicationYear "2020" @default.
• W3024144538 type Work @default.
• W3024144538 sameAs 3024144538 @default.
• W3024144538 citedByCount "0" @default.
• W3024144538 crossrefType "journal-article" @default.
• W3024144538 hasAuthorship W3024144538A5026183878 @default.
• W3024144538 hasAuthorship W3024144538A5043189518 @default.
• W3024144538 hasAuthorship W3024144538A5067858015 @default.
• W3024144538 hasAuthorship W3024144538A5085270072 @default.
• W3024144538 hasAuthorship W3024144538A5086190712 @default.
• W3024144538 hasBestOaLocation W30241445381 @default.
• W3024144538 hasConcept C104317684 @default.
• W3024144538 hasConcept C126322002 @default.
• W3024144538 hasConcept C135763542 @default.
• W3024144538 hasConcept C142462285 @default.
• W3024144538 hasConcept C159047783 @default.
• W3024144538 hasConcept C2779130552 @default.
• W3024144538 hasConcept C2993143319 @default.
• W3024144538 hasConcept C3013748606 @default.
• W3024144538 hasConcept C42407357 @default.
• W3024144538 hasConcept C50605568 @default.
• W3024144538 hasConcept C526171541 @default.
• W3024144538 hasConcept C54355233 @default.
• W3024144538 hasConcept C55775858 @default.
• W3024144538 hasConcept C62231903 @default.
• W3024144538 hasConcept C71924100 @default.
• W3024144538 hasConcept C86745063 @default.
• W3024144538 hasConcept C86803240 @default.
• W3024144538 hasConcept C90924648 @default.
• W3024144538 hasConceptScore W3024144538C104317684 @default.
• W3024144538 hasConceptScore W3024144538C126322002 @default.
• W3024144538 hasConceptScore W3024144538C135763542 @default.
• W3024144538 hasConceptScore W3024144538C142462285 @default.
• W3024144538 hasConceptScore W3024144538C159047783 @default.
• W3024144538 hasConceptScore W3024144538C2779130552 @default.
• W3024144538 hasConceptScore W3024144538C2993143319 @default.
• W3024144538 hasConceptScore W3024144538C3013748606 @default.
• W3024144538 hasConceptScore W3024144538C42407357 @default.
• W3024144538 hasConceptScore W3024144538C50605568 @default.
• W3024144538 hasConceptScore W3024144538C526171541 @default.
• W3024144538 hasConceptScore W3024144538C54355233 @default.
• W3024144538 hasConceptScore W3024144538C55775858 @default.
• W3024144538 hasConceptScore W3024144538C62231903 @default.
• W3024144538 hasConceptScore W3024144538C71924100 @default.
• W3024144538 hasConceptScore W3024144538C86745063 @default.
• W3024144538 hasConceptScore W3024144538C86803240 @default.
• W3024144538 hasConceptScore W3024144538C90924648 @default.
• W3024144538 hasLocation W30241445381 @default.
• W3024144538 hasOpenAccess W3024144538 @default.
• W3024144538 hasPrimaryLocation W30241445381 @default.
• W3024144538 hasRelatedWork W1991772127 @default.
• W3024144538 hasRelatedWork W2032244821 @default.
• W3024144538 hasRelatedWork W2076010627 @default.

• next